Engineered immune cells take on lupus and scleroderma
NCT ID NCT06347718
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This trial tests a one-time treatment using a patient's own immune cells, engineered to target and destroy B cells, which drive autoimmune diseases like lupus, scleroderma, and myositis. 24 adults with active disease will receive the therapy after a short chemotherapy. The main goal is to check safety, but researchers will also look for signs of disease improvement.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
anti-CD19 CAR T cell therapy
What this could lead to
If successful, this could offer a new treatment option for severe autoimmune diseases like lupus and scleroderma, potentially reducing symptoms and disease activity.
What could go wrong
This is an early phase 1/2 trial with only 24 participants, so results may not apply to everyone. Risks include cytokine release syndrome and nerve toxicity, and long-term effects are unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Universitätsklinikum Erlangen
RECRUITINGErlangen, Bavaria, 91054, Germany
Contact
Contact